Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02199184
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:27.954622+00:00
Published At
2024-06-11T00:00:00+00:00
Record Updated At
2024-06-11
Results Posted At
2024-06-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["AIDS-Related Burkitt Lymphoma", "Atypical Burkitt/Burkitt-Like Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Burkitt Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Burkitt Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-06-11"
protocolSection.identificationModule.nctId
"NCT02199184"
protocolSection.identificationModule.officialTitle
"Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-06-11"

Study condition terms

  • AIDS-Related Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Atypical Burkitt/Burkitt-Like Lymphoma (protocolSection.conditionsModule.conditions)
  • High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Burkitt Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.